Behind the Seizure® Program

Sponsored, no-charge genetic testing
Australia

Behind the seizure Australia logo

What is the Behind the Seizure® program?

Invitae, BioMarin Pharmaceutical Australia Pty Ltd., Praxis Precision Medicines, and Xenon Pharmaceuticals Inc. have partnered to offer Invitae's comprehensive Epilepsy Panel to any child 24-95 months of age who has had an unprovoked seizure.

Genetic testing may bring you closer to understanding what’s causing your patient’s epilepsy, helping your patients and their caregivers benefit from deeper knowledge and timely care.

Order now

About Epilepsy

More than 50% of epilepsies have some genetic basis.

When a patient presents with seizures, genetic testing may help identify if there is an underlying genetic cause.1

Many of these genetic variants are tied to actionable medical management.

Identifying a seizure’s underlying etiology may enable disease-specific management strategy.1

Delay can be devastating for patients with genetic epilepsy.

Early diagnosis is critical. Genetic testing can help identify the cause of epilepsy before a patient experiences the hallmark signs of regression.2

Genetic epilepsies may be hiding behind non-specific symptoms.

Language delay and motor disturbance may be useful predictors of finding genetic epilepsies.3

Program eligibility

To be eligible for this program, patients in Australia must meet the following criteria:

  • Any child 24-95 months of age who has had an unprovoked seizure.

Test options

This program offers testing with the following panel. Learn more about the panels in our test catalog before placing your order on this program page.

How to order

Our easy-to-order panels align with professional guidelines, making your potential next steps clearer.

  • Step 1 duotone icon

    Step 1

    Discuss testing and get consent from the eligible patient. Place your order via our convenient online portal.

  • Step 2 duotone icon

    Step 2

    Collect your patient’s specimen using an Invitae collection kit and return it. Use the label provided to ship most samples at no additional charge from the US and Canada.

  • Genetic testing expert - Invitae icon

    Step 3

    Receive results online and access resources to guide your discussion with patient about their results.

See how it works

Next steps and additional services

Our sponsors love working with us

Behind the Seizure is offered in partnership with the following sponsors:

About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for serious and life-threatening rare and ultra-rare genetic diseases. The Company's portfolio consists of seven commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.biomarin.com.au.

About Praxis Precision Medicines
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance. Normal brain function requires a delicate balance of excitation and inhibition in neuronal circuits which, when dysregulated, can lead to abnormal function and disease. Praxis is applying insights into the genetic mutations that drive excitation-inhibition imbalance in diseases to select biological targets for severe pediatric epilepsies and more broadly for prevalent psychiatric diseases and neurologic disorders. Praxis has established a broad portfolio, including five disclosed programs across multiple central nervous system disorders including, depression, epilepsy, movement disorders and pain syndromes, with three clinical-stage product candidates.

About Xenon
Xenon is focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. Building upon our extensive knowledge of diseases caused by mutations in ion channels, Xenon is advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, such as epilepsy, migraine and pain.

References

1. Pal DK, et al. Genetic evaluation and counseling for epilepsy. Nat Rev Neurol. 2010;6:445-453.
2. Nickel M, et al. Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: An observational cohort study. Lancet Child & Adolescent Health. 2018;2(8):582-90.
3. Miller N, Truty R, Bailey M, et al. Behind The Seizure™: A no-cost, 125-gene epilepsy panel for pediatric seizure onset between 2–4 years. Poster presented at the ACMG Annual Clinical Genetics Meeting; April 10–14, 2018; Charlotte, NC.
4. Truty R et al. Possible precision medicine implications from genetic testing using combined detection of sequence and intragenic copy number variants in a large cohort with childhood epilepsy. Epilepsia Open. 2019;10:28.

Disclaimer: This is a sponsored testing program. While third parties and commercial organizations may provide financial support for this program, tests and services are performed by Invitae. Healthcare professionals must confirm that patients meet certain criteria to use the program. Third parties and commercial organizations may receive de-identified (pseudonymized) patient data from this program, but at no time would they receive patient identifiable information. Third parties and commercial organizations may receive contact information for healthcare professionals who use this program. Genetic testing is available in Australia. Healthcare professionals and patients who participate in this program have no obligation to recommend, purchase, order, prescribe, promote, administer, use or support any other products or services from Invitae or from third parties or commercial organizations.